Skip to content

Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control

Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074569
Enrollment
Unknown
Registered
2023-08-09
Start date
2023-08-23
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

WeChat platform group:Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment an
Group of traditional management:None

Sponsors

the First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosed hypertension with age>=18 years old; 2. Clinic blood pressure = 140/90 mmHg; Dynamic blood pressure ABPM shows high blood pressure. If it is inconsistent with the blood pressure in the consultation room, ABPM shall prevail; 3. The patient has and frequently uses their smartphone WeChat to communicate with others (including written interactions); 4. Willing to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Secondary hypertension; 2.Hypertensive emergency: defined as severe elevations in BP (SBP =180 mmHg and/or DBP=120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia; 3.Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist; 4. Cardiovascular events (unstable angina, acute myocardial infarction, stroke) within 3 months before enrollment; 5.Pregnancy or lactation or having pregnancy plan during the study period; 6.Life expectancy less than 1 year; 7.Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university.

Design outcomes

Primary

MeasureTime frame
Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring );

Countries

People's Republic of China

Contacts

Public ContactWu Gaojun

the First Affiliated Hospital of Wenzhou Medical University

2855930357@qq.com+86 137 5871 5199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026